We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01144039
First Posted: June 15, 2010
Last Update Posted: June 16, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Medical University of Vienna
  Purpose

Purpose: The effect of intravenous glutamate infusion on myocardial diastolic function and overall hemodynamics were studied in patients undergoing elective aortic valve replacement with severe aortic stenosis and associated left ventricular hypertrophy .

Methods: 25 patients will be included in this double-blind randomized placebo-controlled study. Glutamate was administered intravenously immediately after aortic cross-clamp release. The patients receive either a low dose of 30mg kg-1 h-1 (LG-group) or high dose of 60 mg kg-1 h-1 (HG-group) or placebo (P-group) at a rate of 3.3ml kg-1h-1 for 2h. Transesophageal echocardiography (TEE) is used to measure diastolic and systolic ventricular function before sternotomy (T0), and 2h (T2), 3h (T3) and 6h (T4) after release of cross clamp. Additionally routine hemodynamic parameters are measured intraoperatively.


Condition Intervention Phase
Hypertrophy, Left Ventricular Aortic Stenosis Myocardial Ischemia Cardiopulmonary Bypass Drug: LG-group Drug: HG-group Drug: Placebo-group Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: Glutamate Infusion in Hypertrophied Ventricle After Aortic Valve Replacement - a Randomized Trial

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • flow propagational velocity
  • Isovolumic relaxation time
  • E-velocity
  • A-velocity
  • E/A ratio

Secondary Outcome Measures:
  • ejection fraction
  • cardiac output
  • mitral ring motion

Enrollment: 27
Study Start Date: February 2006
Study Completion Date: September 2008
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • severe aortic stenosis
  • left ventricular hypertrophy of more than 10mm IVS thickness
  • normal ejection fraction
  • SR

Exclusion Criteria:

  • moderately or severely reduced systolic left ventricular function (ejection fraction <30%)
  • atrial fibrillation or flutter
  • intolerance to glutamate.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01144039


Locations
Austria
Clin. Dept. of Cardiothoracic and Vascular Anaesthesia & Intensive Medicine, Medical University of Vienna, Vienna General Hospital
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
  More Information

ClinicalTrials.gov Identifier: NCT01144039     History of Changes
Other Study ID Numbers: VI_echo_01_2006
First Submitted: June 14, 2010
First Posted: June 15, 2010
Last Update Posted: June 16, 2010
Last Verified: September 2008

Additional relevant MeSH terms:
Ischemia
Myocardial Ischemia
Coronary Artery Disease
Aortic Valve Stenosis
Hypertrophy
Hypertrophy, Left Ventricular
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases
Heart Valve Diseases
Ventricular Outflow Obstruction
Pathological Conditions, Anatomical
Cardiomegaly